Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Alessandro Maggi
Observed names:
A Maggi,
A. Maggi,
Maggi Alessandro,
Maggi, A.,
Maggi, Alessandro
Institution:
Azienda Ospedaliera S.Giuseppe Moscati
Observed institutions:
Città di Castello Hospital,
Azienda Ospedaliera S.Giuseppe Moscati,
Krankenhaus Meran,
Azienda Ospedaliero Universitaria Maggiore della Carita,
Ospedale SS. Annunziata,
Ospedale di Macerata
show all 6
ORCID:
0009-0001-1666-646X
Observed ORCID:
0009-0001-1666-646X
OpenAlex ID:
A5016495018
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
2020
·
Massimo Breccia
, Elisabetta Abruzzese
, et al.
·
Leukemia
·
61
PDF
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice
2018
·
Massimo Breccia
, Elisabetta Abruzzese
, et al.
·
Annals of Hematology
·
40
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network
2021
·
Giorgina Specchia
, Patrizia Pregno
, et al.
·
Frontiers in Oncology
·
24
PDF
Low‐dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs
2020
·
Alessandra Iurlo
, Daniele Cattaneo
, et al.
·
American Journal of Hematology
·
24
PDF
The multi‐tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real‐world data
2020
·
Luigia Luciano
, Mario Annunziata
, et al.
·
European Journal Of Haematology
·
23
PDF
Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study
2022
·
Alessandra Iurlo
, Daniele Cattaneo
, et al.
·
Frontiers in Oncology
·
20
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study
2023
·
A. Iurlo
, D. Cattaneo
, et al.
·
Frontiers in Pharmacology
·
19
Acute leukemia in Jehovah's Witnesses: a challenge for hematologists.
2000
·
P Mazza
, G Palazzo
, et al.
·
PubMed
·
16
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis
2016
·
Massimo Breccia
, Guendalina Graffigna
, et al.
·
Supportive Care in Cancer
·
15
A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin’s lymphoma
2023
·
Francesco Gaudio
, Giacomo Loseto
, et al.
·
Annals of Hematology
·
12
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic‐phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML
2023
·
Mario Tiribelli
, Roberto Latagliata
, et al.
·
Cancer
·
9
PDF
Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial
2021
·
Massimo Breccia
, Luigia Luciano
, et al.
·
Blood
·
8
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials
2024
·
Enrica Antonia Martino
, Daniele Derudas
, et al.
·
Haematologica
·
7
PDF
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study
2025
·
Ernesto Vigna
, Enrica Antonia Martino
, et al.
·
Hematological Oncology
·
6
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data
2025
·
Enrica Antonia Martino
, Annalisa Pitino
, et al.
·
Haematologica
·
6
Dasatinib first-line: Multicentric Italian experience outside clinical trials
2015
·
Massimo Breccia
, Fabio Stagno
, et al.
·
Leukemia Research
·
6
Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort
2026
·
Enrica Antonia Martino
, Annalisa Pitino
, et al.
·
Blood Advances
·
5
PDF
Plerixafor in association with R-DHAP and G-CSF to mobilize a large number of CD34 + cells in patients with relapsed-refractory diffuse large B-cell lymphomas
2024
·
Francesco Gaudio
, Anna Mele
, et al.
·
Annals of Hematology
·
5
Chronic myeloid leukemia outcomes according to baseline risk and first‐line treatment in real‐world settings: Data from the Italian Network/CML Campus
2025
·
Valentina Giai
, Tiziana Rosso
, et al.
·
Cancer
·
4
Early progression beyond first‐line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study
2024
·
Alberto Bavieri
, Maria E. Nizzoli
, et al.
·
HemaSphere
·
4
PDF
Choice of Frontline Tyrosine‐Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A “Campus CML ” Study
2024
·
C. Bucelli
, I. Capodanno
, et al.
·
European Journal Of Haematology
·
4
PDF
Outcomes of mixed phenotype acute leukemia undergoing allogeneic stem cell transplantation: a retrospective study of the ALWP of EBMT
2026
·
Annalisa Paviglianiti
, Maud Ngoya
, et al.
·
Bone Marrow Transplantation
·
3
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience
2024
·
Giuseppe Mele
, Daniele Derudas
, et al.
·
Annals of Hematology
·
3
The Use of 2 nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2 nd Generation TKIs
2023
·
Valentina Giai
, Fabio Stagno
, et al.
·
Blood
·
3
Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact (D-IMPACT) Project
2026
·
Elisabetta Abruzzese
, Monica Crugnola
, et al.
·
Cancers
·
2
Show more works
View as search
Works count:
59
Citation count:
345
H-index:
10
I10-index:
10
Year
Topic
Type